Delayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|5|1643-1650

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.5, 2015-05, pp. : 1643-1650

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MELDEQ: An alternative Model for End‐Stage Liver Disease score for patients with hepatocellular carcinoma

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 5, 2015-05 ,pp. : 612-622

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcomes for liver transplant candidates listed with low model for end‐stage liver disease score

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 11, 2015-11 ,pp. : 1403-1409

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Risk of End‐Stage Renal Disease Among Living Donor Liver Transplant Recipients in the United States

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 1600-6135, Iss. 10, 2015-10 ,pp. : 2732-2738

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Risk of End‐Stage Renal Disease Among Living Donor Liver Transplant Recipients in the United States

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 15, Iss. 10, 2015-10 ,pp. : 2732-2738

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adding C‐reactive protein and procalcitonin to the model of end‐stage liver disease score improves mortality prediction in patients with complications of cirrhosis

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 3, 2018-03 ,pp. : 726-732

John Wiley & Sons Inc

Access to resources Recommend Favorite